Early Success of Gene-Editing Therapy in Advanced Gastrointestinal Cancers

Researchers at the University of Minnesota have conducted a pioneering clinical trial utilizing CRISPR/Cas9 gene-editing technology to bolster the immune system's ability to combat advanced gastrointestinal (GI) cancers. Published in The Lancet Oncology, the study reveals promising indications of both safety and potential efficacy of this innovative treatment.

The trial involved modifying tumor-infiltrating lymphocytes (TILs) by disabling a gene called CISH. This genetic alteration enhanced the T cells’ capacity to recognize and attack cancer cells. The treatment was administered to 12 patients with highly metastatic, end-stage GI cancers. Findings demonstrated that the gene editing process was well tolerated, with no serious adverse effects reported.

Several participants experienced stabilization of their cancer growth, and notably, one patient achieved complete tumor regression, with metastatic tumors disappearing over several months and remaining absent for more than two years.

Leading the research, Dr. Emil Lou emphasized that despite advances in understanding cancer genetics, stage IV colorectal cancer remains largely incurable. This trial signifies a transformative step, translating laboratory innovations into clinical practice with the potential to improve outcomes for late-stage cancer patients.

The core of the approach involved editing the TILs to deactivate CISH, a gene that hampers T cell tumor recognition. Unlike conventional therapies requiring ongoing administration, the gene edits made in this study are permanent, embedding themselves into the immune cells from the outset. This is achieved through a one-step CRISPR process that permanently modifies the T cells, which can then efficiently seek out and attack tumors.

The team successfully produced over 10 billion engineered TILs without adverse side effects, demonstrating that large-scale genetic engineering of immune cells is feasible in a clinical setting. However, the process remains complex and costly, necessitating further efforts to streamline production and understand the mechanisms behind the therapy’s success. Future research aims to optimize the treatment and broaden its applicability.

This groundbreaking study underscores the potential of gene-editing as a powerful tool in cancer immunotherapy, opening new avenues for tackling cancers previously deemed incurable.